Implications of binding mode and active site flexibility for inhibitor potency against the salicylate synthase from Mycobacterium tuberculosis
Chi, G., Manos-Turvey, A., O'Connor, P.D., Johnston, J.M., Evans, G.L., Baker, E.N., Payne, R.J., Lott, J.S., Bulloch, E.M.(2012) Biochemistry 51: 4868-4879
- PubMed: 22607697 
- DOI: 10.1021/bi3002067
- Primary Citation of Related Structures:  
3VEH, 3RV6, 3RV7, 3RV8, 3RV9, 3ST6 - PubMed Abstract: 
MbtI is the salicylate synthase that catalyzes the first committed step in the synthesis of the iron chelating compound mycobactin in Mycobacterium tuberculosis. We previously developed a series of aromatic inhibitors against MbtI based on the reaction intermediate for this enzyme, isochorismate ...